Influence of Different Thresholds for Asthma Control on Clinical Remission Composite Outcome in Patients Uncontrolled on ICS/LABA: A Post-hoc Analysis of Single Inhaler Triple Therapy With FF/UMEC/VI in the CAPTAIN Trial

被引：0
|
作者：
Oppenheimer, J. [1 ]
Pavord, I. [2 ,3 ]
Crawford, J. [4 ]
Corbridge, T. [5 ]
Howarth, P. [6 ]
Igboekwe, E. [5 ]
Moore, A. [6 ]
Noorduyn, S. G. [7 ]
Plank, M. [6 ]
Slade, D. [8 ]
Weng, S. [9 ]
Lugogo, N. [10 ]
机构：
[1] Rutgers New Jersey Med Sch, Newark, NJ USA
[2] Resp Med Unit, Oxford, England
[3] Oxford Resp NIHR BRC, Oxford, England
[4] GSK, Dev Biostat, Brentford, England
[5] GSK, US Med Affairs, Durham, NC USA
[6] GSK, Global Med Affairs, Brentford, England
[7] GSK, R&D Global Med, Value Evidence & Outcomes, Mississauga, ON, Canada
[8] GSK, US Med Affairs, Collegeville, PA USA
[9] GSK, Resp Biostat, Stevenage, Herts, England
[10] Univ Michigan, Sch Med, Dept Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48104 USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2024年 / 209卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A5267
引用
收藏
页数：2
相关论文
共 15 条
  • [1] Is Asthma Clinical Remission Achievable by Inhaled Therapy? A Post-Hoc Analysis of Single Inhaler Triple Therapy with FF/UMEC/VI in the CAPTAIN Trial
    Lugogo, Njira
    Oppenheimer, John
    Crawford, Jodie
    Corbridge, Tom
    Howarth, Peter
    Igboekwe, Emmeline
    Moore, Alison
    Noorduyn, Stephen
    Slade, David
    Weng, Stephen
    Pavord, Ian
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB266 - AB266
  • [2] Impact of varying lung function threshold on clinical remission in asthma with FF/UMEC/VI: CAPTAIN post hoc analysis
    Oppenheimer, John
    Pavord, Ian
    Crawford, Jodie
    Gould, Stephen
    Hamouda, Mohamed
    Igboekwe, Emmeline
    Moore, Alison
    Noorduyn, Stephen G.
    Slade, David
    Weng, Stephen
    Lugogo, Njira
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [3] Single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the China cohort in the IMPACT trial
    Zheng, Jinping
    Zhong, Nanshan
    Wang, Changzheng
    Wei, Li Ping
    Zhou, Xiang Dong
    Zhao, Li
    Dong Yuan, Ya
    He, Bei
    Wu, Bin
    Du, Xin
    Song, Jie
    Lipson, David A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (01) : 145 - 155
  • [4] Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)
    Meredith McCormack
    Rosirene Paczkowski
    Noelle N. Gronroos
    Stephen G. Noorduyn
    Lydia Lee
    Phani Veeranki
    Mary G. Johnson
    Emmeline Igboekwe
    Kristin Kahle-Wrobleski
    Reynold Panettieri
    Advances in Therapy, 2024, 41 : 1245 - 1261
  • [5] Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)
    Mccormack, Meredith
    Paczkowski, Rosirene
    Gronroos, Noelle N.
    Noorduyn, Stephen G.
    Lee, Lydia
    Veeranki, Phani
    Johnson, Mary G.
    Igboekwe, Emmeline
    Kahle-Wrobleski, Kristin
    Panettieri, Reynold
    ADVANCES IN THERAPY, 2024, 41 (03) : 1245 - 1261
  • [6] An Analysis of the IMPACT Trial Assessing Single-Inhaler Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI and UMEC/VI Using a Composite Adverse Event Outcome in Patients with COPD
    Wells, J. M.
    Bhatt, S. P.
    Carr, T. F.
    Criner, G. J.
    Halpin, D. M. G.
    Han, M. K.
    Jain, R.
    Kaye, M. G.
    Kraft, M.
    Lipson, D. A.
    Mapel, D.
    Mammen, M. J.
    McEvoy, C.
    Midwinter, D.
    Singh, D.
    Wise, R.
    Dransfield, M. T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [7] Reduction in All-Cause Mortality with Single Inhaler Triple Therapy (FF/UMEC/VI) Versus Dual Therapy (FF/VI and UMEC/VI) in Symptomatic Patients with COPD: Prespecified Analysis of the Phase III IMPACT Trial
    Lipson, D. A.
    Barnhart, F.
    Brealey, N.
    Day, N. C.
    Brooks, J.
    Criner, G.
    Dransfield, M. T.
    Halpin, D. M.
    Han, M. K.
    Jones, C.
    Kilbride, S.
    Lange, P.
    Lomas, D. A.
    Martinez, F. J.
    Singh, D.
    Tabberer, M.
    Wise, R. A.
    Pascoe, S. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [8] Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial
    Lee, Laurie A.
    Bailes, Zelie
    Barnes, Neil
    Boulet, Louis-Philippe
    Edwards, Dawn
    Fowler, Andrew
    Hanania, Nicola A.
    Kerstjens, Huib A. M.
    Kerwin, Edward
    Nathan, Robert
    Oppenheimer, John
    Papi, Alberto
    Pascoe, Steven
    Brusselle, Guy
    Peachey, Guy
    Sule, Neal
    Tabberer, Maggie
    Pavord, Ian D.
    LANCET RESPIRATORY MEDICINE, 2021, 9 (01): : 69 - 84
  • [9] THE IMPACT TRIAL: COST-EFFECTIVENESS ANALYSIS OF SINGLE-INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS DUAL BRONCHODILATOR THERAPY (UMEC/VI) IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN SPAIN
    Vallejo-Aparicio, L. A.
    Paly, V. F.
    Schroeder, M.
    Martin, A.
    Risebrough, N.
    Abreu, C.
    Biswas, C.
    Izquierdo Alonso, J. L.
    Riesco Miranda, J. A.
    Soler Cataluna, J. J.
    Ismaila, A. S.
    VALUE IN HEALTH, 2019, 22 : S878 - S878
  • [10] Unveiling the Clinical Profiles for Patients With Asthma and Chronic Obstructive Pulmonary Disease Starting Single-inhaler Triple Therapy With Fluticasone Furoate/Umeclidinium/Vilanterol (FF/ UMEC/VI)
    Narendra, D.
    Baptist, A. P.
    Lee, L.
    Noorduyn, S. G.
    Liu, M.
    Igboekwe, E. E.
    Veeranki, P.
    Kahle-Wrobleski, K.
    Paczkowski, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
12